Clinical trials have shown the efficacy of interferon (IFN) alpha in a number of lymphoproliferative diseases and in solid tumours such as melanoma and renal cancer. Most of these studies were performed according to classical protocols of anticancer chemotherapy, using maximal tolerated doses or doses giving highest serum IFN concentrations. However, the best results, including a high percentage of complete remissions, were obtained in hairy cell leukaemia with relatively low doses of IFN-alpha (3 x 106 units/day or three times weekly, Flandrin et al., 1986) which give hardly detectable serum levels (Lodemann et al., 1985) . To establish a rationale for the clinical trial of lower IFN doses, which are associated with less side-effects, it seems important to determine the relative biological activities of lower doses of IFN. We have thus studied three responses specifically induced in peripheral blood mononuclear cells (PBMC) of cancer patients by the standard dose of 3 x 106 IU IFN-alpha and by a tenfold lower dose (0.3 x 106 IU). These responses were the down-regulation of membrane IFN-alpha receptors, previously shown to occur in vivo (Billard et al., 1986; Maxwell et al., 1985) , the antiviral state, and (2'-5') oligoadenylate (2-5A) synthetase activity which is a sensitive marker of IFN therapy (Schattner et al., 1981; Merritt et al., 1986) .
The study was carried out on six patients with metastatic renal cell carcinoma, entering a phase IT clinical trial performed with natural IFN-alpha. This IFN has been purified from human leukocytes according to the Cantell's method (Cantell et al., 1981) Table I . Differential white cell counts were performed using May- (Aguet & Blanchard, 1981) . The 2-SA synthetase activity was measured by an assay described earlier (Justesen et al., 1980) . Antiviral state was evaluated by an adaptation of the technique of Levin & Hahn (1981 The number of receptor sites/cell decreased markedly without affinity changes within 24 h after the first dose of 0.3 x 106 IU, resulting in a receptor down-regulation of about 70% at 48 h. This latter was then reversed, resulting in a complete recovery of the initial number of receptors. An 80% decrease in the number of receptors/cell was induced as soon as 6 h after the 3 x 106 IU dose, as previously observed (Billiard et al., 1986) , increasing gradually after 24 h. Therefore, the receptor down-regulation was of similar amplitude with both IFN doses. Measurements of 2-5A synthetase activity (basic level 0.6 nmol AMP min-10-7 cells) showed induction within 12 h after injection of 0.3 x 106 IU, with maximal stimulation at 24h. The plateau value was maintained for an additional 24 h to decrease rapidly thereafter, recovering the pretreatment level by 168 h. While the rate of induction seemed higher with the dose of 3 x 106 IU, the maximal stimulation of 2-SA synthetase activity was the same as that obtained with 0.3 x 106 IU. An antiviral state was induced in PBMC within 24h after each IFN dose. One thousand-fold inhibition in viral multiplication was observed after both doses. The antiviral state remained stable for -48h in both cases then declined in parallel thereafter.
White cell counts in peripheral blood revealed a marked lymphopenia as soon as 6 h after injection of each of the two doses, which was completely reversed by 48 h. On the contrary, neutrophils did not show any particular pattern of modification (data not shown).
Similar results were observed with the five other patients examined (Table TI) (Billard et al., 1986; Lau et al., 1986; Maxwell et al., 1985) . The observation that the dose of 0.3 x 106 IU is able to induce the same effect on IFN-receptor interaction, which is the first step in IFN action, is of great interest. Although its role in the antitumour effect of IFN remains to be established, receptor down-regulation is currently thought to reflect the state of responsiveness to IFN (Billard et al., 1986; Maxwell et al., 1985) .
The enzyme 2-5A synthetase is a biochemical pathway induced by IFNs and is thought to be involved in their antiviral action (Lengyel, 1982) . Whether this enzyme also plays a role in other properties of IFN is not known, although changes in 2-5A synthetase activity were associated with cell growth and differentiation in different systems (see Rossi, 1985, for review) . Basic levels of the enzyme differed depending on the patients, and the extents of stimulation after i.m. administration in the dose range studied here were in agreement with those previously reported by Lodeman et al. (1985) and Merritt et al. (1986) . However, the range of dose-response relationship reported by Merritt et al. (1986) was wider.
We also show that PBMC from cancer patients who were treated with single doses of IFN-alpha (Herberman, 1983 with IFN, rather than maximal tolerated doses, and that daily administrations might not be needed. In this respect, it has recently been reported that such low doses as 0.5 x 106 IU IFN-alpha or low frequency protocols were successfully used in the treatment of hairy cell leukaemia with reduced side effects (Berneman et al., 1986; Hiuber et al., 1985; Porzsolt et al., 1985) .
